Dragonfly Therapeutics and Gilead Sciences Collaborate to Develop Cancer Treatment Prospects

Dragonfly Therapeutics and Gilead Sciences have partnered to develop two cancer treatment prospects, DF1001 and Trodelvy.  

The research will leverage insight into the treatment’s effects on lung and metastatic breast cancer.  

DF1001 has previously exhibited the potential to increase immunity to tumour-inducing properties for those not improving under current treatments. The prospect is one of the most advanced in Dragonfly’s portfolio, which is developing treatments for several disease types.  

Joseph Eid, the head executive of Dragonfly’s Research sector, stated, “DF1001 is the first of eight Dragonfly-developed drugs in the clinic and has shown clinical benefit in mBC, NSCLC, and colorectal cancer in a heterogeneous Phase I population with 22% RECIST [a standard method to show how a cancer patient responds to a therapy] responders and 39% clinical benefit in mBC patients at active dose levels, with no dose-limiting toxicities even in a heavily-pre-treated population.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.